Overreliance on any single biomarker should be avoided in favor of integrative approaches that combine PD-L1 status with tumor-infiltrating lymphocytes, immune-related gene signatures, and liquid biopsy markers such as circulating tumor DNA. The gene discussed is CD274; the disease is neoplasm.